A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
Intravenous KO-947 had a generally tolerable safety profile with minimal gastrointestinal toxicity compared with oral administration of other ERK inhibitors.
Authors
- Jasmine H. Francis (ORCID: https://orcid.org/0000-0002-7637-3108)
- María Vieito (ORCID: https://orcid.org/0000-0001-7531-343X)
- V. Boni
- Julie Mackey Ahsan
- Birgitta Tomkinson
- E. Garralda
- Anthony J. Olszanski (ORCID: https://orcid.org/0000-0001-5276-5898)
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Michael R. Kurman
- Alex A. Adjei (ORCID: https://orcid.org/0000-0002-8039-6556)
Institutions
- Boston University (US)
- Fox Chase Cancer Center (US)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Hospital Universitario Quirónsalud Madrid (ES)
- Hospital Quirónsalud Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Kura Oncology (United States) (US)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104300
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- American Society of Clinical Oncology
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Mersana Therapeutics
- BeiGene
- Boston Pharmaceuticals
- Incyte
- Relay Therapeutics
- Puma Biotechnology
- MacroGenics
- Astellas Pharma
- Shionogi
- Genentech
- Takeda Oncology
- Loxo Oncology
- Principia Biopharma
- National Cancer Institute
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe